Hemispherian is a pioneering brand in the field of epigenetic cancer therapies, offering a dynamic pipeline of next-generation treatments. Committed to revolutionizing cancer treatment and patient care, Hemispherian conducts ongoing research, preclinical studies, and clinical trials. The brand specializes in developing a novel class of small molecule drugs that target the TET2 enzyme, particularly for aggressive cancers.

Hemispherian's lead compound is currently in late stage preclinical development for glioblastoma multiforme, a deadly cancer of the central nervous system. Their targeted therapeutics act on a new mechanism of action, restoring a cancer cell's normal epigenetic complement. By triggering the DNA damage response, these drugs bring about cancer cytotoxicity.

Notably, the treatment is highly focused on cancers and is well tolerated in normal tissues. Supported by several Norwegian and European public entities, Hemispherian is always seeking new partnerships to expand its network. Contact them if you'd like to contribute to the vital work of bringing these groundbreaking drugs into clinics